Indivior CUD study fails to meet primary and secondary endpoints

(Sharecast News) - Drugmaker Indivior said on Wednesday that the primary and secondary endpoints of Aelis Farma's clinical Phase 2B study of AEF0117 use in participants with cannabis use disorder had not been met. Indivior said the purpose of the trial was twofold - to show that AEF0117 lowers cannabis use and to determine the endpoints and optimal dosage of AEF0117 for use in future studies.

However, the London-listed group stated the results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to less than one day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used less than two days per week, were not met.

"Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD," said Indivior.

"Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favourable clinical data, Indivior does not currently expect to exercise its option."

As of 0850 BST, Indivior shares were down 1.86% at 896.0p.









Reporting by Iain Gilbert at Sharecast.com